Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology

Go back to Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1152.93 +0.49 (0.04%)
Previous Close $1152.44    52 Week High $88.16 
Open $1150.00    52 Week Low $67.88 
Day High $1157.60    P/E 266.88 
Day Low $1140.27    EPS $4.32 
Volume 4,549,709